首页> 外文期刊>The Journal of Urology >Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
【24h】

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

机译:细胞减少性肾切除术用于转移性肾细胞癌,细胞组织学不清楚。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To our knowledge the benefit of cytoreductive surgery for patients with metastatic renal cell carcinoma with nonclear cell histology is unknown. In this retrospective study we report our experience with cytoreductive nephrectomy for nonclear cell metastatic renal cell carcinoma at M. D. Anderson Cancer Center. We compared the outcomes with those in patients with clear cell metastatic renal cell carcinoma. MATERIALS AND METHODS: From 1991 to 2006, 606 patients with metastatic renal cell carcinoma underwent cytoreductive nephrectomy and they formed the basis of this report. Of these patients 92 had nonclear cell metastatic renal cell carcinoma. The remaining 514 patients had clear cell metastatic renal cell carcinoma and they formed a comparative group. Multivariate Cox regression analysis was performed to evaluate the relationship between clinical variables and histology (clear cell vs nonclear cell) on disease specific survival. RESULTS: Compared with patients with clear cell histology those with nonclear cell metastatic renal cell carcinoma were younger (p = 0.0001), and more likely to have nodal metastases (p <0.0001) and sarcomatoid features (23% vs 13%, p = 0.026). On multivariate analysis median disease specific survival in patients with nonclear cell histology was significantly worse than that in patients with clear cell metastatic renal cell carcinoma (9.7 vs 20.3 months, p = 0.0003) even after adjusting for T stage, grade, performance status, age and sarcomatoid features. Sarcomatoid features were a predictor of poor outcome in cases of clear and nonclear cell histology, although even in the absence of sarcomatoid features nonclear cell histology was associated with worse disease specific survival (p = 0.017). Interestingly although there was a significantly higher incidence of positive nodes in patients with nonclear histology (p <0.0001), this phenotype was not associated with a worse disease specific survival, as it was in those with clear cell histology (p = 0.0001). In fact, patientswith node negative disease with nonclear cell histology had the worst prognosis overall in the entire group. CONCLUSIONS: Patients with nonclear cell metastatic renal cell carcinoma were younger and had a higher incidence of nodal metastases, a higher incidence of sarcomatoid features and a worse prognosis than those with clear cell histology who underwent cytoreductive surgery.
机译:目的:据我们所知,对于组织学不清楚的转移性肾细胞癌患者,进行细胞减灭术的益处尚不清楚。在这项回顾性研究中,我们在安德森癌症中心(M. D. Anderson Cancer Center)报告了细胞减少性肾切除术治疗非透明细胞转移性肾细胞癌的经验。我们将结果与透明细胞转移性肾细胞癌患者的结果进行了比较。材料与方法:从1991年至2006年,共606例转移性肾细胞癌患者接受了细胞减灭性肾切除术,这是本报告的基础。这些患者中有92例患有非透明细胞转移性肾细胞癌。其余514例患者患有透明细胞转移性肾细胞癌,他们组成了一个比较组。进行多变量Cox回归分析以评估临床变量与组织学(透明细胞与非透明细胞)之间在疾病特异性存活率上的关系。结果:与具有透明细胞组织学的患者相比,具有非透明细胞转移性肾细胞癌的患者更年轻(p = 0.0001),并且更有可能发生淋巴结转移(p <0.0001)和肉瘤样特征(23%vs 13%,p = 0.026) )。在多因素分析中,即使在调整了T分期,等级,行为状态和年龄之后,非透明细胞组织学患者的中位疾病特异性生存率也明显高于透明细胞转移性肾细胞癌患者(9.7 vs 20.3个月,p = 0.0003)。和肉瘤样特征。尽管在没有肉瘤样特征的情况下,不清晰的细胞组织学也与较差的疾病特异性存活率相关(p = 0.017),但肉瘤样特征在透明和不透明的细胞组织学病例中是不良预后的预测指标。有趣的是,尽管在组织学不清楚的患者中阳性淋巴结的发生率明显更高(p <0.0001),但这种表型与疾病特异性生存率的降低没有关系,就像在具有清晰细胞组织学的患者中(p = 0.0001)。实际上,在整个组织中,淋巴结阴性疾病的细胞组织学不清楚的患者的总体预后最差。结论:非透明细胞转移性肾细胞癌的患者较接受细胞减灭术的具有透明细胞组织学的患者更年轻,淋巴结转移的发生率更高,肉瘤样特征的发生率更高且预后更差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号